10th Dec 2012 11:44
Monday 10 December 2012
Allergy Therapeutics plc
('Allergy Therapeutics' or the 'Company')
Director/PDMR Shareholding
Allergy Therapeutics announces that on 10 December 2012 Mr Ian Postlethwaite, a director of the Company, exercised share options over 1,500,000 ordinary shares of 0.1 pence each ('Ordinary Shares') awarded pursuant to the Allergy Therapeutics 2001 Share Option Plan-Enterprise Management Incentive Scheme as follows:
Name of scheme: Allergy Therapeutics 2001 Share Option Plan -Enterprise Management Incentive
Date of grant: 17 December 2002
Date of exercise: 10 December 2012
Exercise price: 5 pence
Number of Ordinary Shares resulting from exercise of options: 1,500,000
On the same day, Mr Postlethwaite sold 140,000 Ordinary Shares at a trade price of 12.5 pence per share to contribute towards the tax and exercise costs of the options.
Following the above transactions, Mr Postlethwaite now holds 1,360,000 Ordinary Shares (representing 0.33 per cent. of the total voting rights of the Company), share options over 163,500 Ordinary Shares and LTIPs over 1,320,000 Ordinary Shares.
The total number of Ordinary Shares in issue (inclusive of the above issue) is 409,842,981.
Application has been made for the admission to trading on AIM ("Admission") of 1,500,000 Ordinary Shares with Admission expected to take place on 14 December 2012. The Ordinary Shares will rank pari passu in all respects with the existing ordinary share capital of the Company.
For further information
Allergy Therapeutics | +44 (0) 1903 845 820 |
Manuel Llobet, Chief Executive Officer | |
www.allergytherapeutics.com | |
Nomura Code Securities | +44 (0) 207 776 1200 |
Juliet Thompson/ Clare Terlouw | |
FTI Consulting | +44 (0) 207 831 3113 |
Simon Conway / Susan Stuart / Victoria Foster Mitchell |
Related Shares:
Allergy Thera.